Literature DB >> 17942705

Elevated level of SUMOylated IRF-1 in tumor cells interferes with IRF-1-mediated apoptosis.

Junsoo Park1, Kwangsoo Kim, Eun-Ju Lee, Yun-Jee Seo, Si-Nae Lim, Kyoungsook Park, Seung Bae Rho, Seung-Hoon Lee, Je-Ho Lee.   

Abstract

SUMOylation of transcription factors often attenuates transcription activity. This regulation of protein activity allows more diversity in the control of gene expression. Interferon regulatory factor-1 (IRF-1) was originally identified as a regulator of IFN-alpha/beta, and its expression is induced by viral infection or IFN stimulation. Accumulating evidence supports the theory that IRF-1 functions as a tumor suppressor and represses the transformed phenotype. Here we report that the level of SUMOylated IRF-1 is elevated in tumors. Site-directed mutagenesis experiments disclose that the SUMOylation sites of IRF-1 are identical to the major ubiquitination sites. Consequently, SUMOylated IRF-1 displays enhanced resistance to degradation. SUMOylation of IRF-1 attenuates its transcription activity, and SUMOylated IRF-1 inhibits apoptosis by repression of its transcriptional activity. These data support a mechanism whereby SUMOylation of IRF-1 inactivates its tumor suppressor function, which facilitates resistance to the immune response.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17942705      PMCID: PMC2040422          DOI: 10.1073/pnas.0609852104

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  31 in total

Review 1.  Modification with SUMO. A role in transcriptional regulation.

Authors:  Alexis Verger; José Perdomo; Merlin Crossley
Journal:  EMBO Rep       Date:  2003-02       Impact factor: 8.807

2.  SUMO-1 modification represses Sp3 transcriptional activation and modulates its subnuclear localization.

Authors:  Sarah Ross; Jennifer L Best; Leonard I Zon; Grace Gill
Journal:  Mol Cell       Date:  2002-10       Impact factor: 17.970

3.  Tumor-suppressor effect of interferon regulatory factor-1 in human hepatocellular carcinoma.

Authors:  Y Moriyama; S Nishiguchi; A Tamori; N Koh; Y Yano; S Kubo; K Hirohashi; S Otani
Journal:  Clin Cancer Res       Date:  2001-05       Impact factor: 12.531

4.  Interferon gamma (IFNgamma ) and tumor necrosis factor alpha synergism in ME-180 cervical cancer cell apoptosis and necrosis. IFNgamma inhibits cytoprotective NF-kappa B through STAT1/IRF-1 pathways.

Authors:  K Suk; I Chang; Y H Kim; S Kim; J Y Kim; H Kim; M S Lee
Journal:  J Biol Chem       Date:  2001-01-18       Impact factor: 5.157

Review 5.  Nuclear and unclear functions of SUMO.

Authors:  Jacob-S Seeler; Anne Dejean
Journal:  Nat Rev Mol Cell Biol       Date:  2003-09       Impact factor: 94.444

Review 6.  SUMO in cancer--wrestlers wanted.

Authors:  Dania Alarcon-Vargas; Ze'ev Ronai
Journal:  Cancer Biol Ther       Date:  2002 May-Jun       Impact factor: 4.742

7.  PIAS3 induces SUMO-1 modification and transcriptional repression of IRF-1.

Authors:  Koji Nakagawa; Hideyoshi Yokosawa
Journal:  FEBS Lett       Date:  2002-10-23       Impact factor: 4.124

8.  Degradation of transcription factor IRF-1 by the ubiquitin-proteasome pathway. The C-terminal region governs the protein stability.

Authors:  K Nakagawa; H Yokosawa
Journal:  Eur J Biochem       Date:  2000-03

9.  Alternative splicing variants of IRF-1 lacking exons 7, 8, and 9 in cervical cancer.

Authors:  Eun-Ju Lee; Minwha Jo; Junsoo Park; Wei Zhang; Je-Ho Lee
Journal:  Biochem Biophys Res Commun       Date:  2006-07-05       Impact factor: 3.575

10.  SUMO modification of Huntingtin and Huntington's disease pathology.

Authors:  Joan S Steffan; Namita Agrawal; Judit Pallos; Erica Rockabrand; Lloyd C Trotman; Natalia Slepko; Katalin Illes; Tamas Lukacsovich; Ya-Zhen Zhu; Elena Cattaneo; Pier Paolo Pandolfi; Leslie Michels Thompson; J Lawrence Marsh
Journal:  Science       Date:  2004-04-02       Impact factor: 47.728

View more
  23 in total

1.  Overexpression of SUMO-1 in hepatocellular carcinoma: a latent target for diagnosis and therapy of hepatoma.

Authors:  Wu-Hua Guo; Li-Hua Yuan; Zhi-Hua Xiao; Dan Liu; Ji-Xiang Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2010-05-26       Impact factor: 4.553

2.  Replacement of the C-terminal tetrapeptide (314 PAPV 317 to 314 SSSM 317) in interferon regulatory factor-2 alters its N-terminal DNA-binding activity.

Authors:  Krishna Prakash; Pramod C Rath
Journal:  J Biosci       Date:  2010-12       Impact factor: 1.826

Review 3.  IRF7: activation, regulation, modification and function.

Authors:  S Ning; J S Pagano; G N Barber
Journal:  Genes Immun       Date:  2011-04-14       Impact factor: 2.676

4.  SUMOylation of pancreatic glucokinase regulates its cellular stability and activity.

Authors:  Ingvild Aukrust; Lise Bjørkhaug; Maria Negahdar; Janne Molnes; Bente B Johansson; Yvonne Müller; Wilhelm Haas; Steven P Gygi; Oddmund Søvik; Torgeir Flatmark; Rohit N Kulkarni; Pål R Njølstad
Journal:  J Biol Chem       Date:  2013-01-07       Impact factor: 5.157

5.  A multiprotein binding interface in an intrinsically disordered region of the tumor suppressor protein interferon regulatory factor-1.

Authors:  Vikram Narayan; Petr Halada; Lenka Hernychová; Yuh Ping Chong; Jitka Žáková; Ted R Hupp; Borivoj Vojtesek; Kathryn L Ball
Journal:  J Biol Chem       Date:  2011-01-18       Impact factor: 5.157

6.  Growth factor-induced phosphorylation of sterol regulatory element-binding proteins inhibits sumoylation, thereby stimulating the expression of their target genes, low density lipoprotein uptake, and lipid synthesis.

Authors:  Mitsumi Arito; Taro Horiba; Satoshi Hachimura; Jun Inoue; Ryuichiro Sato
Journal:  J Biol Chem       Date:  2008-04-09       Impact factor: 5.157

7.  SUMOylation of RhoGDIα is required for its repression of cyclin D1 expression and anchorage-independent growth of cancer cells.

Authors:  Zipeng Cao; Xueyong Li; Jingxia Li; Beipei Kang; Jingyuan Chen; Wenjing Luo; Chuanshu Huang
Journal:  Mol Oncol       Date:  2013-12-03       Impact factor: 6.603

8.  RelAp43, a member of the NF-κB family involved in innate immune response against Lyssavirus infection.

Authors:  Sophie Luco; Olivier Delmas; Pierre-Olivier Vidalain; Frédéric Tangy; Robert Weil; Hervé Bourhy
Journal:  PLoS Pathog       Date:  2012-12-13       Impact factor: 6.823

9.  The IRF family of transcription factors: Inception, impact and implications in oncogenesis.

Authors:  Hideyuki Yanai; Hideo Negishi; Tadatsugu Taniguchi
Journal:  Oncoimmunology       Date:  2012-11-01       Impact factor: 8.110

10.  Function and mechanism by which interferon regulatory factor-1 inhibits oncogenesis.

Authors:  Fei-Fei Chen; Guan Jiang; Kerui Xu; Jun-Nian Zheng
Journal:  Oncol Lett       Date:  2012-11-28       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.